Tepotinib

From Wikipedia, the free encyclopedia
Tepotinib
Tepotinib.svg
Tepotinib ball-and-stick 4R1V.png
Clinical data
Trade namesTepmetko
Other namesEMD-1214063
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • Not recommended
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H28N6O2
Molar mass492.583 g·mol−1
3D model (JSmol)
SMILES
InChI

Tepotinib, sold under the brand name Tepmetko, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.[1][2][3] It is a c-Met inhibitor, a type of tyrosine kinase inhibitor.

Tepotinib first received marketing approval in Japan, in March 2020, as a "line-agnostic" drug, meaning it is approved both for treatment-naive patients and for those in whom previous attempts at treatment have failed.[4] U.S. approval followed in February 2021. It is the second therapy approved by the U.S. Food and Drug Administration (FDA) to treat non-small cell lung cancer with these particular mutations, after capmatinib.[citation needed]

Medical uses[]

Tepotinib is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.[1][2]

Adverse effects[]

The most common side effects seen in clinical trials were edema, fatigue, nausea, diarrhea, muscle aches, and shortness of breath. Like capmatinib, tepotinib can also cause interstitial lung disease and liver damage, and is toxic to a developing fetus.[2]

References[]

  1. ^ Jump up to: a b c "Tepmetko- tepotinib hydrochloride tablet". DailyMed. Retrieved 13 February 2021.
  2. ^ Jump up to: a b c d "FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer". 3 February 2021. Retrieved 3 February 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ Jump up to: a b "FDA Approves Tepmetko as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations". EMD Serono (Press release). 3 February 2021. Retrieved 3 February 2021.
  4. ^ "Tepmetko (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations" (Press release). Merck KGaA. 2020-03-25. Retrieved 3 February 2021.

Further reading[]

External links[]

  • "Tepotinib". Drug Information Portal. U.S. National Library of Medicine.
  • "Tepotinib hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
  • "Tepotinib hydrochloride". NCI Drug Dictionary. National Cancer Institute.
  • Clinical trial number NCT02864992 for "Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (VISION)" at ClinicalTrials.gov
Retrieved from ""